Genmab

	17/5 11:50 af Helge Larsen/PI-redaktør	Sorry Stroka at jeg blandede mig. Jeg troede at du havde glemt noget af meddelelsen.
	17/5 11:48 af Stroka	Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 240,306 shares as treasury shares, corresponding to 0.37% of the total share capital and voting rights.
	17/5 11:43 af Stroka	The following transactions were executed under the program from May 10, 2021 to May 14, 2021: # No. of shares Average price (DKK) Total value (DKK) Accumulated through last announcement 136,800 286,652,775 May 10, 2021 1,400 2,286.59 3,201,226 May 11, 2021 1,400 2,228.91 3,120,474 May 12, 2021 May 13, 2021 1,500 0 2,243.32 N/A 3,364,980 0 May 14, 2021 0 N/A 0 Total 4,300 9,686,680 Accumulated under the program 141,100 296,339,455
	17/5 11:43 af Stroka	17.5.2021 10.34 · GlobeNewswire Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; May17, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than June 30, 2021 and comprises up to 200,000 shares....
	17/5 09:41 af Helge Larsen/PI-redaktør	Aktier/åbning: Ambu, Genmab og Ørsted til tops i grøn åbning (link)
	17/5 09:16 af Helge Larsen/PI-redaktør	Flot Stockbull. :-)
	17/5 09:09 af TeamGarlic	God formiddag :-)
	17/5 09:07 af StockBull	Hold da op. Nu skete det sku igen. Havde genmabber til salg til 2270 som blev solgt i 2307 i åbningen. Kanon
	17/5 08:47 af Helge Larsen/PI-redaktør	Genmab har fået et nyt kursmål, efter at JPMorgan har løftet sit kursmål til 2500 kr. fra 2350 kr. Genmab-aktien steg onsdag 0,1 pct. til 2231 kr.: (link)
	17/5 08:17 af B.Andersen	God morgen . :-)
	17/5 07:30 af Stroka	God morgen. :-)
	17/5 07:10 af Doublo	God morgen...(link)
	17/5 06:46 af Helge Larsen/PI-redaktør	Vi mangler stadig flere spørgsmål til Q&A.
	17/5 06:42 af Helge Larsen/PI-redaktør	Mandagens aviser med ISS, TDC og Novo Nordisk (link)
	17/5 06:40 af Helge Larsen/PI-redaktør	Asien: Stærkt blandede markeder - kursfald i Tokyo (link)
	17/5 06:39 af Helge Larsen/PI-redaktør	God morgen. :-)
	16/5 19:07 af Helge Larsen/PI-redaktør	Kursgraf: Efter en positiv fredag er der igen mulighed for et teknisk brud op i biotek sektoren. (link)
	16/5 19:06 af Helge Larsen/PI-redaktør	Langers Skarpe: Sektorrotation holder markedet oppe (link)
	16/5 19:02 af Helge Larsen/PI-redaktør	Servicemeddelelse. Efter lang tids analyse, gennemgang og omkodning i et 12 år gammelt maskinrum tror vi, at uploadsproblemet i debatten er tæt på en løsning. :-) Kør endelig løs og meld tilbage ved evt. fejl.
	15/5 10:43 af E L	good find gentogen , that is the Phase 3
	15/5 10:09 af Helge Larsen/PI-redaktør	Genmab Genmab 32,624 followers 1d • Edited • 1 day ago During today's The New York Academy of Sciences virtual symposium, A Kate Sasser, Senior VP, Head of Translation Research will be speaking at 3:55 PM EST on the Frontiers in Cancer Immunotherapy. Join Kate and other industry thought leaders at (link)
	15/5 08:58 af Helge Larsen/PI-redaktør	Spørgsmåll til Q&A er meget velkommen. :-)
	14/5 21:44 af gentogen	The EU CT Register shows two clinical for Mim8 (link)
	14/5 20:39 af Bulder	I’ll ask Winkel if he has any idea.

	14/5 20:37 af Bulder	Hemophelia market is pretty big, but don’t know what it means on share price. Depends I suppose on market share. (link)
	14/5 16:36 af E L	Have any Novo watchers put any value against this product yet? Not sure what value to put on this for now...
	14/5 16:31 af E L	Nobody answered, but i am pretty sure it is MIM-8 with FDA orphan designation "12/5 15:40 af E L I assume this is MIM-8 / Novo Nordisk ? Orphan Designation (link)"
	14/5 16:17 af Helge Larsen/PI-redaktør	Genmab @Genmab · 15m Our virtual #ASCO21 booth is now live. Visit to learn about our innovative pipeline, next-generation antibody platforms and data presentations at the 2021 @ASCO Annual Meeting: (link)
	14/5 15:57 af Bulder	Almindelig opgang i går og rally i dag. Det giver lidt at indhente på mandag
	14/5 15:40 af StockBull	nu 37.22
	14/5 15:40 af StockBull	37.02 usd - kurs 2275
	14/5 12:58 af Bulder	ADS’en steg pænt i går selvom NBI hang lidt med næbbet. Bliver interessant i dag, hvor det meste er grønt og Vix nede med 20%.
	14/5 07:42 af Helge Larsen/PI-redaktør	Udover Q&A mandag har ProInvestor sammen med Nordnet biotekwebinar med Genmab, Bavarian og Zealand Pharma tirsdag. Tlmelding: (link)
	14/5 07:37 af Helge Larsen/PI-redaktør	Spørgsmål til Q&A er meget velkommen. :-)
	14/5 07:03 af Helge Larsen/PI-redaktør	God morgen. :-)
	14/5 06:33 af Plimsoller	God morgen :-)
	13/5 14:40 af Bulder	Futterne begynder så småt at grønnes. Vix nede med 8%
	13/5 14:23 af Bulder	Dax'en ser ud til at rette sig efter at have været nede med 2% i formiddags. Nu minus 0,5%
	13/5 14:10 af Legolas23	Der er vel også et økonomisk aspekt epco Vs Glofi ?
	13/5 13:26 af Bulder	On the safety-side epco clearly has the advantage of only making CRS grade 1 or 2, where glofi is associated with some cases of grade 3 and 4.
	13/5 12:43 af GeorgeBest	we still to have wait to see if Glofi comes with a subcu version, but if not epco clearly looks like a potential winner
	13/5 12:41 af GeorgeBest	11:39 agree E L, for me epco also looks best-in-class :-)
	13/5 12:40 af Bulder	Ser ud til at Dax'en lader sig inspirere af us-nedtur i går. Futterne dog ikke helt så røde.
	13/5 12:25 af Bulder	Nice that you got the conclusion from Cass part 2 before they locked it up. :-)
	13/5 12:18 af Bulder	I suppose we'll soon see a filing of dara as maintenance.
	13/5 12:17 af Bulder	Thx E L. Yes, the shift from PR to CR is impressing.
	13/5 11:49 af E L	I think AEs looked probably a bit high with some grade 3/4 neutropenia and anemia, but looking at above conclusion it looks as if they think they can improve that with a different dosing strategie
	13/5 11:47 af E L	Conclusion Talquetamab, at the RP2D of weekly 405 μg/kg SC, demonstrated a high clinical response rate and was well-tolerated in patients with relapsed/refractory MM. Based on the pharmacokinetic data, other SC dosing strategies are also being explored. The promising efficacy and safety profile, and the convenience of SC dosing support monotherapy development and combination approaches with this novel agent.
	13/5 11:47 af E L	It is rather annoying that EHA have embargoed some abstracts again, I copied this on Talquetamab yesterday:
	13/5 11:39 af E L	I find the comparisson with Glofitamab a bit difficult, they are longer into the trial (27 months? vs 14 months). If i can compare Glofi DLBCL ORR of 41.1% (n = 30), with CR in 28.8% (n = 21). And FL ORR 55.2% and CR 34.5%, Epco clearly seems better?